Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPV116910 ofatumumab in pemphigus vulgaris
2013-001370-20Phase 3Terminated
- Sponsor
- GSK
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pemphigus vulgaris (PV) comparing Ofatumumab arm with Placebo arm (2 arms). Primary endpoints: Co-primary efficacy endpoints (remission-based) and Safety and tolerability. Started Aug 2014; status: terminated.
02
Drugs
ofatumumab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on 2013-001370-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001370-20.